Trastuzumab Deruxtecan-Induced Interstitial Lung Disease/Pneumonitis in ERBB2-Positive Advanced Solid Malignancies: A Systematic Review

BACKGROUND AND OBJECTIVE: Trastuzumab deruxtecan (T-DXd) is a novel anti-ERBB2 antibody drug conjugate that appears to be associated with an increased risk of lung toxicity. We performed a systematic review to describe the incidence, severity, and management of T-DXd-induced interstitial lung diseas...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuhelwa, Ziad, Alloghbi, Abdurahman, Alqahtani, Ali, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276583/
https://www.ncbi.nlm.nih.gov/pubmed/35759121
http://dx.doi.org/10.1007/s40265-022-01736-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276583/
https://www.ncbi.nlm.nih.gov/pubmed/35759121
http://dx.doi.org/10.1007/s40265-022-01736-w

Ejemplares similares